Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40SKF | ISIN: US67054R2031 | Ticker-Symbol: N86
Tradegate
23.01.25
18:59 Uhr
24,970 Euro
-0,530
-2,08 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
NUKKLEUS INC Chart 1 Jahr
5-Tage-Chart
NUKKLEUS INC 5-Tage-Chart
RealtimeGeldBriefZeit
25,78526,24019:14
PR Newswire
350 Leser
Artikel bewerten:
(2)

Nukkleus, Inc. Achieves Strategic Milestone with Acquisition of a Controlling Stake in Star 26 a Defense-focus acquisition company and a provider of Israel's Iron Dome Missile Defense System

Finanznachrichten News

JERSEY CITY, NJ, Dec. 17, 2024 /PRNewswire/ -- Dec 17, 2024 - Nukkleus, Inc. (NASDAQ: NUKK), a pioneer in the fintech sector traditionally focused on the cryptocurrency market, announced that it has successfully acquired a 51% controlling stake in Star 26 Capital Inc., a defense acquisition company holding 95% ownership in RIMON. RIMON is a leading Israeli supplier of critical components for the Iron Dome missile defense system, as well as other defense and tactical solutions.

The transaction, finalized on December 15, 2024, involved a total purchase price of $26 million, including cash, a promissory note Nukkleus ' s common stock, and warrants to purchase additional shares of common stock of Nukkleus. This acquisition also includes an option agreement allowing Nukkleus to acquire the remaining equity in Star 26 at a later date.

With this acquisition, Nukkleus gains control over RIMON's diversified operations, which include two key business lines:

Distribution of Generators, masts and Lighting Solutions: RIMON operates through exclusive distributorship agreements with leading suppliers.

Development of Tactical Vehicles: RIMON designs, engineers, and integrates tactical vehicles, including reconnaissance vehicles, mobile command and control units, and satellite broadcast platforms, serving special defense forces, intelligence agencies, and the Israeli Defense Forces (IDF).

Manny Shalom, the newly appointed CEO of Nukkleus and a seasoned entrepreneur in the security sector, stated " This merger positions Nukkleus at the forefront of a booming defense industry. Our acquisition of Star 26 and RIMON aligns with our strategic pivot to capitalize on opportunities in the defense sector, which has seen rapid growth due to geopolitical shifts in the Middle East and the war in Ukraine. This has resulted in a surge of investments and acquisitions in Israeli defense firms such as PARAGON and PROTEGO, alongside a 120% increase in Israel ' s defense indices and a 38% rise in similar indices in the US."

He added "RIMON's expertise in critical defense systems, coupled with its established partnerships with leading defense exporters like Rafael and Elbit Systems, strengthens Nukkleus ' s capabilities in delivering innovative defense solutions."

As part of its expansion strategy, Nukkleus plans to integrate Star 26 operations into its business structure while exploring further growth opportunities. The company will also plans to broaden its activities into other sectors, serving as a Merchant Bank for companies in banking, U.S. real estate, and technology-populated coworking space campus locations, leveraging its financial expertise to seize emerging opportunities in the changing region of the middle east.

Looking Ahead

The combined entity will focus on the Israeli and US market opportunities - acquiring controlling interest in medium-sized companies while providing them financing and global business development opportunities. With a shared commitment to innovation and excellence, Nukkleus and Star are poised to drive growth and deliver value to shareholders, customers, and stakeholders alike.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the anticipated benefits of the acquisition, expected market trends, and future performance. Actual results may differ materially due to various factors. For a detailed discussion of these risks, please refer to Nukkleus's filings with the Securities and Exchange Commission (SEC).

Contact:

Yair Ohayon
CMO
[email protected]

SOURCE Nukkleus, Inc.

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.